Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1A | P36894 | 7/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660640 | 0.88 | PIK3CA (0.42) | BMPR1AACVRL1ACVR1AKT1MTOR | |
| SCHEMBL4920565 | 0.85 | PDE4A (0.36) | BMPR1AACVRL1ACVR1PDE4A | |
| SCHEMBL2669594 | 0.84 | BMPR1A (0.40) | BMPR1AACVRL1ACVR1GABRA1AKT1 | |
| SCHEMBL2661662 | 0.82 | CNR1 (0.39) | MTORPDE4A | |
| SCHEMBL2669389 | 0.81 | PIK3CA (0.38) | BMPR1AACVRL1ACVR1MTORPDE4A | |
| SCHEMBL2658514 | 0.80 | — | — | |
| SCHEMBL2661936 | 0.80 | MAPK1 (0.35) | BMPR1AACVRL1ACVR1PDE4A | |
| SCHEMBL2657367 | 0.80 | MTOR (0.38) | BMPR1AACVRL1ACVR1GABRA1AKT1 | |
| SCHEMBL2660625 | 0.79 | GABRG2 (0.39) | — | |
| SCHEMBL2660241 | 0.79 | ABCC9 (0.33) | BMPR1AACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | BMPR1A 1929/4885ACVRL1 3949/4885ACVR1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.